TP53 and metastatic malignant neoplasm in the lymph nodes: Other clinicopathologic factors found to be associated with RFS included age > 50 years (HR, 3.925; 95% CI, 1.182–13.038), postmenopausal status (HR, 3.487; 95% CI, 1.197–10.160), nonendometrioid carcinoma (HR, 7.964; 95% CI, 3.568–17.776), FIGO grade 3 (HR, 5.472; 95% CI, 2.571–11.646), advanced stage (FIGO stages III–IV) (HR, 5.069; 95% CI, 2.318–11.084), lymphovascular invasion (HR, 3.280; 95% CI, 1.522–7.071), lymph node metastasis (HR, 2.837; 95% CI, 1.143–7.042), and p53 mutant pattern (HR, 4.628; 95% CI, 2.136–10.024) (Table 4).